CN105154499A - L-天门冬氨酸-l-鸟氨酸的制备方法 - Google Patents
L-天门冬氨酸-l-鸟氨酸的制备方法 Download PDFInfo
- Publication number
- CN105154499A CN105154499A CN201510635360.3A CN201510635360A CN105154499A CN 105154499 A CN105154499 A CN 105154499A CN 201510635360 A CN201510635360 A CN 201510635360A CN 105154499 A CN105154499 A CN 105154499A
- Authority
- CN
- China
- Prior art keywords
- aspartic acid
- arginine
- preparation
- ornithine
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003104 ornithine Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 104
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 55
- 229930064664 L-arginine Natural products 0.000 claims abstract description 55
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000008367 deionised water Substances 0.000 claims abstract description 45
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 45
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 43
- 108010093096 Immobilized Enzymes Proteins 0.000 claims abstract description 42
- 238000003756 stirring Methods 0.000 claims abstract description 36
- 239000004793 Polystyrene Substances 0.000 claims abstract description 23
- 239000004005 microsphere Substances 0.000 claims abstract description 23
- 229920002223 polystyrene Polymers 0.000 claims abstract description 23
- 238000002425 crystallisation Methods 0.000 claims abstract description 17
- 230000008025 crystallization Effects 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 14
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 10
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 9
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 9
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229940071125 manganese acetate Drugs 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 42
- 238000001976 enzyme digestion Methods 0.000 claims description 30
- 239000012530 fluid Substances 0.000 claims description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004202 carbamide Substances 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 abstract description 20
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 12
- 150000003839 salts Chemical class 0.000 abstract description 7
- 102000004452 Arginase Human genes 0.000 abstract description 3
- 108700024123 Arginases Proteins 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- 229940099596 manganese sulfate Drugs 0.000 abstract 1
- 235000007079 manganese sulphate Nutrition 0.000 abstract 1
- 239000011702 manganese sulphate Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000001514 detection method Methods 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229940023913 cation exchange resins Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229910001422 barium ion Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 0 *CCC[C@](C(O)=O)N Chemical compound *CCC[C@](C(O)=O)N 0.000 description 1
- 241000370738 Chlorion Species 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- -1 vitriol Chemical compound 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
批次 | 酶解反应转化时间 | 酶解反应转化率 | 终产品总收率 | 终产品含量 |
1 | 2h | 99.38% | 86.94% | 98.53% |
2 | 3h | 99.43% | 86.01% | 98.66% |
3 | 3h | 99.26% | 86.25% | 98.57% |
4 | 3h | 99.18% | 87.67% | 98.55% |
5 | 4h | 99.34% | 87.11% | 98.57% |
6 | 4h | 99.28% | 87.52% | 98.68% |
7 | 5h | 99.16% | 86.50% | 98.62% |
8 | 5h | 99.24% | 88.28% | 98.76% |
9 | 5h | 99.08% | 89.63% | 99.02% |
10 | 5h | 99.13% | 88.55% | 99.43% |
编号 | 总收率(%) | 终产品含量(%,液相外标法) | 比旋光度[α]D 20 |
实施例1 | 86.9% | 99.0 | +27.1 |
实施例2 | 86.3% | 98.7 | +27.8 |
实施例3 | 86.7% | 98.8 | +27.9 |
实施例4 | 83.2% | 98.3 | +26.8 |
实施例5 | 81.8% | 97.9 | +26.3 |
实施例6 | 80.5% | 98.1 | +26.5 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510635360.3A CN105154499B (zh) | 2015-09-30 | 2015-09-30 | L-天门冬氨酸-l-鸟氨酸的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510635360.3A CN105154499B (zh) | 2015-09-30 | 2015-09-30 | L-天门冬氨酸-l-鸟氨酸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105154499A true CN105154499A (zh) | 2015-12-16 |
CN105154499B CN105154499B (zh) | 2018-11-09 |
Family
ID=54795542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510635360.3A Active CN105154499B (zh) | 2015-09-30 | 2015-09-30 | L-天门冬氨酸-l-鸟氨酸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105154499B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107522629A (zh) * | 2017-10-12 | 2017-12-29 | 福建金山生物制药股份有限公司 | 一种门冬氨酸鸟氨酸的制备方法 |
CN107540413A (zh) * | 2017-09-14 | 2018-01-05 | 精晶药业股份有限公司 | 一种从门冬氨酸鸟氨酸结晶母液中提取尿素的方法 |
CN108440324A (zh) * | 2018-04-19 | 2018-08-24 | 成都倍特药业有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
CN110590919A (zh) * | 2017-05-24 | 2019-12-20 | 中国海洋大学 | 含鸟氨酸的短肽及其应用 |
CN112342253A (zh) * | 2020-11-10 | 2021-02-09 | 湖南天成生化科技有限公司 | 高收率l-精氨酸硝酸盐的制备方法 |
CN113336663A (zh) * | 2021-06-04 | 2021-09-03 | 无锡晶海氨基酸股份有限公司 | 一种利用鸟氨酸催化液制备门冬氨酸鸟氨酸的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102041282A (zh) * | 2009-10-14 | 2011-05-04 | 新沂市汉菱生物工程有限公司 | 酶法制备l-鸟氨酸的方法 |
CN102102118A (zh) * | 2009-12-18 | 2011-06-22 | 上海汉飞生化科技有限公司 | 一种l-鸟氨酸-l-天门冬氨酸盐的制备方法 |
CN102286602A (zh) * | 2011-09-16 | 2011-12-21 | 天津启仁医药科技有限公司 | 微生物酶法拆分dl-精氨酸制备d-精氨酸盐酸盐和l-鸟氨酸盐酸盐的方法 |
-
2015
- 2015-09-30 CN CN201510635360.3A patent/CN105154499B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102041282A (zh) * | 2009-10-14 | 2011-05-04 | 新沂市汉菱生物工程有限公司 | 酶法制备l-鸟氨酸的方法 |
CN102102118A (zh) * | 2009-12-18 | 2011-06-22 | 上海汉飞生化科技有限公司 | 一种l-鸟氨酸-l-天门冬氨酸盐的制备方法 |
CN102286602A (zh) * | 2011-09-16 | 2011-12-21 | 天津启仁医药科技有限公司 | 微生物酶法拆分dl-精氨酸制备d-精氨酸盐酸盐和l-鸟氨酸盐酸盐的方法 |
Non-Patent Citations (1)
Title |
---|
周炜清等: "高分子大孔微球的制备和结构控制", 《化工学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110590919A (zh) * | 2017-05-24 | 2019-12-20 | 中国海洋大学 | 含鸟氨酸的短肽及其应用 |
CN110590919B (zh) * | 2017-05-24 | 2022-05-24 | 中国海洋大学 | 含鸟氨酸的短肽及其应用 |
CN107540413A (zh) * | 2017-09-14 | 2018-01-05 | 精晶药业股份有限公司 | 一种从门冬氨酸鸟氨酸结晶母液中提取尿素的方法 |
CN107522629A (zh) * | 2017-10-12 | 2017-12-29 | 福建金山生物制药股份有限公司 | 一种门冬氨酸鸟氨酸的制备方法 |
CN108440324A (zh) * | 2018-04-19 | 2018-08-24 | 成都倍特药业有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
CN108440324B (zh) * | 2018-04-19 | 2021-04-20 | 成都倍特药业股份有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
CN112342253A (zh) * | 2020-11-10 | 2021-02-09 | 湖南天成生化科技有限公司 | 高收率l-精氨酸硝酸盐的制备方法 |
CN113336663A (zh) * | 2021-06-04 | 2021-09-03 | 无锡晶海氨基酸股份有限公司 | 一种利用鸟氨酸催化液制备门冬氨酸鸟氨酸的方法 |
CN113336663B (zh) * | 2021-06-04 | 2023-08-22 | 无锡晶海氨基酸股份有限公司 | 一种利用鸟氨酸催化液制备门冬氨酸鸟氨酸的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105154499B (zh) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105154499A (zh) | L-天门冬氨酸-l-鸟氨酸的制备方法 | |
CN103613709B (zh) | 以马铃薯淀粉黄原酸酯为原料合成吸附重金属离子专用树脂的方法 | |
CN104059167B (zh) | 一种多胺化合物修饰磁性壳聚糖的制备方法及其应用 | |
CN103007892A (zh) | 一种磁性高分子复合微球的制备方法 | |
CN102688752A (zh) | 一种β-环糊精接枝碳纳米管吸附材料的制法和用途 | |
CN102162030A (zh) | 一种离子交换分离钨酸盐和钼酸盐混合溶液中钨钼的方法 | |
CN104892710B (zh) | 一种纯化还原型β‑烟酰胺腺嘌呤二核苷酸的方法 | |
CN103263894B (zh) | 一种尿激酶快速吸附袋 | |
CN101456903A (zh) | 万古霉素的分离纯化方法 | |
CN106831894B (zh) | 一种脱乙酰基耦合吸附分离d-氨基葡萄糖盐酸盐的方法 | |
WO2018107377A1 (zh) | 一种nadph的纯化工艺 | |
AU2020103503A4 (en) | Boric acid adsorbent material and preparation method | |
CN104211739B (zh) | 一种泰乐菌素的精制方法 | |
CN108970589B (zh) | 一种水滑石基复合凝胶球及其制备方法和应用 | |
CN104450662A (zh) | 一种利用离子交换纤维固定化果糖基转移酶的制备方法 | |
CN105536832B (zh) | 介孔磷酸铌催化剂的制备方法及其在山梨醇制异山梨醇中的应用 | |
WO2020147421A1 (zh) | 一种舒更葡糖的分离纯化方法 | |
CN105295059A (zh) | 一种固载阳离子化β-环糊精的氯甲基化聚苯乙烯聚合物及吸附回收工业废水中酚类的方法 | |
CN103951665B (zh) | 新型托品醇类氨基酸阴离子型手性离子液体的制备、固定化及其拆分dl-苯丙氨酸和dl-色氨酸的方法 | |
CN100554417C (zh) | 海藻酸-碳酸钙杂化凝胶固定β-葡萄糖醛酸苷酶的方法 | |
CN101607893B (zh) | 从食用级枸橼酸获得药用级枸橼酸的方法 | |
CN104152508A (zh) | 直接从生产栀子黄色素的废液中提取京尼平的方法 | |
CN102219716A (zh) | 一种5-磺基水杨酸的纯化方法 | |
CN103193837B (zh) | 制备硫酸依替米星的方法 | |
CN106995390B (zh) | 一种减少促进剂二苯胍生产过程中废水产生的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of L-aspartate L-ornithine Effective date of registration: 20230418 Granted publication date: 20181109 Pledgee: Hebei Ningjin Rural Commercial Bank Co.,Ltd. Pledgor: JING JING PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980038366 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231114 Granted publication date: 20181109 Pledgee: Hebei Ningjin Rural Commercial Bank Co.,Ltd. Pledgor: JING JING PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980038366 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of L-aspartate L-ornithine Effective date of registration: 20231204 Granted publication date: 20181109 Pledgee: Hebei Ningjin Rural Commercial Bank Co.,Ltd. Pledgor: JING JING PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980069369 |